Dyslipidemias (eBook)
XVI, 525 Seiten
Humana Press (Verlag)
978-1-60761-424-1 (ISBN)
Dyslipidemias: Pathophysiology, Evaluation and Management provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children. Covering the full range of common through rare lipid disorders, this timely resource offers targeted, practical information for all clinicians who care for patients with dyslipidemias, including general internists, pediatric and adult endocrinologists, pediatricians, lipidologists, cardiologists, internists, and geneticists. For the last twenty years, there has been a growing recognition worldwide of the importance of managing dyslipidemia for the primary and secondary prevention of atherosclerotic vascular disease, especially coronary heart disease. This has been mainly due to the publication of the guidelines of National Cholesterol Education Program's Adult Treatment Panel and Pediatric Panel from the United States. These guidelines have stimulated generation of similar recommendations from all over the world, particularly Europe, Canada, Australia and Asia. Developed by a renowned group of leading international experts, the book offers state-of-the-art chapters that are peer-reviewed and represent a comprehensive assessment of the field. A major addition to the literature, Dyslipidemias: Pathophysiology, Evaluation and Management is a gold-standard level reference for all clinicians who are challenged to provide the best care and new opportunities for patients with dyslipidemias.
Abhimanyu Garg, MBBS, MD
Professor of Internal Medicine
UT Southwestern Medical Center
Department of Internal Medicine
5323 Harry Hines Blvd
Dallas, TX 75390
TEL 214-648-2895
Dyslipidemias: Pathophysiology, Evaluation and Management provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children. Covering the full range of common through rare lipid disorders, this timely resource offers targeted, practical information for all clinicians who care for patients with dyslipidemias, including general internists, pediatric and adult endocrinologists, pediatricians, lipidologists, cardiologists, internists, and geneticists. For the last twenty years, there has been a growing recognition worldwide of the importance of managing dyslipidemia for the primary and secondary prevention of atherosclerotic vascular disease, especially coronary heart disease. This has been mainly due to the publication of the guidelines of National Cholesterol Education Program's Adult Treatment Panel and Pediatric Panel from the United States. These guidelines have stimulated generation of similar recommendations from all over the world, particularly Europe, Canada, Australia and Asia. Developed by a renowned group of leading international experts, the book offers state-of-the-art chapters that are peer-reviewed and represent a comprehensive assessment of the field. A major addition to the literature, Dyslipidemias: Pathophysiology, Evaluation and Management is a gold-standard level reference for all clinicians who are challenged to provide the best care and new opportunities for patients with dyslipidemias.
Abhimanyu Garg, MBBS, MDProfessor of Internal MedicineUT Southwestern Medical CenterDepartment of Internal Medicine5323 Harry Hines BlvdDallas, TX 75390TEL 214-648-2895
Chapter 1. Lipoprotein Physiology Chapter 2. Epidemiology of Blood Lipids and Lipoproteins Chapter 3. Lipoprotein(a) Chapter 4. Lipoproteins and Cardiovascular Disease Risk Chapter 5. Detection and Treatment of Children and Adolescents with Dyslipidemia Chapter 6. Type 2 Diabetes Mellitus and Dyslipidemia Chapter 7. Type 1 Diabetes Mellitus and Dyslipidemia Chapter 8. Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome Chapter 9. Dyslipidemia in HIV-infected PatientsChapter 10. Monogenic Hypercholesterolemia Chapter 11. Primary Hypertriglyceridemia Chapter 12. Genetic Disorders of HDL Metabolism Chapter 13. Sitosterolemia and Other Rare Sterol Disorders Chapter 14. Genetic Abetalipoproteinemia & Hypobetalipoproteinemia Chapter 15. Drug-induced Dyslipidemia Chapter 16. Lipodystrophies and Dyslipidemias Chapter 17. Novel Genes for Dyslipidemias: Genome-Wide Association Studies Chapter 18. Perspectives on Cholesterol GuidelinesChapter 19. Nutrition and Coronary Heart Disease Prevention Chapter 20. Phytosterol Therapy Chapter 21. N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease Chapter 22. Polyphenols for Cholesterol Management Chapter 23 - Dietary Supplements for Cholesterol ManagementChapter 24. Statins: Risk-Benefits and Role in Treating Dyslipidemias Chapter 25. Fibrates: Risk-Benefits and Role in Treating Dyslipidemias Chapter 26. Niacin: Risk-Benefits and Role in Treating Dyslipidemias Chapter 27. Bile Acid Sequestrants: Risk-Benefits and Role in Treating DyslipidemiasChapter 28. Cholesterol Absorption Inhibitor-Ezetimibe: Risk-Benefits and Role in Treating Dyslipidemias Chapter 29. Low Density Lipoprotein (LDL) ApheresisChapter 30. Novel Lipid Lowering Agents
| Erscheint lt. Verlag | 11.5.2015 |
|---|---|
| Reihe/Serie | Contemporary Endocrinology | Contemporary Endocrinology |
| Zusatzinfo | XVI, 525 p. 127 illus., 101 illus. in color. |
| Verlagsort | Totowa |
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Gesundheitswesen |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Allgemeinmedizin | |
| Medizinische Fachgebiete ► Innere Medizin ► Endokrinologie | |
| Medizinische Fachgebiete ► Innere Medizin ► Kardiologie / Angiologie | |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Pädiatrie | |
| Schlagworte | Abetalipoproteinemia • Chronic Kidney Disease • Drug-induced dyslipidemia • Dyslipidemia • Familial lipodystrophies • Genetic disorders of HDL metabolism • Genetic hypobetalipoproteinemia • lipoprotein • Monogenic hypercholesterolemia • Monogenic hypertriglyceridemia • Nutritional Therapy • Phytosterol therapy • Polygenic dyslipidemia • Sitosterolemia • Type 1 Diabetes • type 2 diabetes • Type III dyslipidemia |
| ISBN-10 | 1-60761-424-3 / 1607614243 |
| ISBN-13 | 978-1-60761-424-1 / 9781607614241 |
| Haben Sie eine Frage zum Produkt? |
PDF (Wasserzeichen)Größe: 19,4 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
